Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial

被引：0
|
作者：
Freedman, M. [1 ]
Wolinsky, J. [2 ]
Comi, G. [3 ]
Kappos, L. [4 ]
Olsson, T. [5 ]
Miller, A. [6 ]
Benamor, M. [7 ]
Dukovic, D. [8 ]
Liang, J. [8 ]
Truffinet, P. [7 ]
O'Connor, P. [9 ]
机构：
[1] Ottawa Hosp, Ottawa, ON, Canada
[2] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Basel, Basel, Switzerland
[5] Karolinska Inst, Stockholm, Sweden
[6] Ichan Sch Med Mt Sinai, New York, NY USA
[7] Sanofi, Chilly Mazarin, France
[8] Sanofi, Bridgewater, MA USA
[9] Univ Toronto, Toronto, ON, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [1] Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Comi, Giancarlo
    Kappos, Ludwig
    Hu, Xueqiang
    Xu, Xianhao
    Lublin, Alex L.
    Truffinet, Philippe
    Chavin, Jeffrey
    Delhay, Jean-Luc
    Benamor, Myriam
    Purvis, Annie
    Freedman, Mark S.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [2] Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
    Miller, Aaron E.
    [J]. NEURODEGENERATIVE DISEASE MANAGEMENT, 2013, 3 (05) : 467 - 483
  • [3] Long-term Efficacy and Safety Outcomes of Teriflunomide Treatment in TEMSO and TOWER
    Oh, Jiwon
    Freedman, Mark S.
    Benamor, Myriam
    Poole, Elizabeth
    Chavin, Jeffrey
    Comi, Giancarlo
    [J]. NEUROLOGY, 2018, 90
  • [4] Long-term Efficacy of Teriflunomide in Patients Recently Diagnosed With Relapsing Forms of MS
    Oh, Jiwon
    Freedman, Mark S.
    Miller, Aaron E.
    Thangavelu, Karthinathan
    Truffine, Philippe
    Comi, Giancarlo
    [J]. NEUROLOGY, 2017, 88
  • [5] Long-term efficacy of teriflunomide in patients recently diagnosed with relapsing forms of MS
    Freedman, M.
    Comi, G.
    Miller, A.
    Wolinsky, J.
    Oh, J.
    Thangavelu, K.
    Truffinet, P.
    Kappos, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 666 - 666
  • [6] Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
    Miller, Aaron E.
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (12) : 381 - 396
  • [7] Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial
    O'Connor, Paul
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Wolinsky, Jerry
    Olsson, Tomas P.
    Miller, Aaron
    Freedman, Mark S.
    [J]. MULTIPLE SCLEROSIS, 2008, 14 : S85 - S85
  • [8] Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
    Andrew Chan
    Jérôme de Seze
    Manuel Comabella
    [J]. CNS Drugs, 2016, 30 : 41 - 51
  • [9] LONG-TERM SAFETY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Hauser, Stephen
    Cross, Anne
    Winthrop, Kevin
    Wiendl, Heniz
    Nicholas, Jacqueline
    Meuth, Sven
    Giacomini, Paul
    Sacca, Francesco
    Su, Wendy
    Kappos, Ludwig
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [10] LONG-TERM EFFICACY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Hauser, Stephen
    Fox, Edward
    Aungst, Angela
    Su, Wendy
    Zielman, Ronald
    Das Gupta, Ayan
    Stoneman, Dee
    Robertson, Derrick
    Cohen, Jeffrey
    Kappos, Ludwig
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
12345